Richard Martin, MD
Rheumatology · Grand Rapids, MINPI 1215924642
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,500 of the $7,588 with a category attached, or 98.8%. AbbVie accounts for 99.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $7,510 and has fallen 99.2% since, to $63 in 2021.
Across 5 payments — averaging $1517.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Genentech USA, Inc.$50
- Johnson & Johnson$28
Across 42 payments — averaging $2460.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$103K
What the payments were for
- Consulting fees$7,50099%
- Food & beverage$380%
- Education$501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 2 | $7,510 |
| Genentech USA, Inc. | 1 | $50 |
| Johnson & Johnson | 2 | $28 |
How this compares
$7,588 in reported general payments places this provider in the 65th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 177 | $1,404,586 |
| RinvoqUpadacitinib | 77 | $697,358 |
| EnbrelEtanercept | 71 | $506,607 |
| Humira(Cf) PenAdalimumab | 75 | $500,075 |
| Actemra ActpenTocilizumab | 37 | $217,078 |
| Orencia ClickjectAbatacept | 29 | $175,828 |
| Humira(Cf)Adalimumab | 15 | $139,171 |
| OrenciaAbatacept | 24 | $136,550 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $117,054 |
| Cosentyx (2 Syringes)Secukinumab | 13 | $97,232 |
| Cosentyx SyringeSecukinumab | 12 | $84,520 |
| MethotrexateMethotrexate Sodium | 900 | $46,520 |
| Adalimumab-Adaz(Cf) PenAdalimumab-Adaz | 24 | $29,215 |
| Leflunomide | 262 | $25,375 |
| Mycophenolate Mofetil | 38 | $9,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $7,510 | $836,52992 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in Grand Rapids
- Barakat ThabetGrand Rapids$128K
- Zhe LiangGrand Rapids$41K
- Mohamed MohamedGrand Rapids$11K
- Brett CapelGrand Rapids$9K
- John FlemingGrand Rapids$9K
- Nour ZleikGrand Rapids$8K
- Saja AlmaaitahGrand Rapids$8K
- Amar MajjhooSaint Clair Shores$1.8M
- Andrew SulichSaint Clair Shores$1.7M
- Dinesh KhannaAnn Arbor$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.